AF-FLOW Registry to Evaluate Electrographic Flow Mapping in Patients Undergoing Ablation for Atrial Fibrillation

Completed

Conditions studied: Atrial Fibrillation, Persistent, Atrial Fibrillation, Arrhythmias, Cardiac, Heart Diseases

In brief

This post-market global registry will evaluate the ability of Electrographic Flow (EGF™) mapping to identify atrial fibrillation (AF) sources and guide ablation therapy in patients with atrial fibrillation in real-world setting.

Key facts

Study ID

NCT05481359

Run by

Ablacon, Inc.

People needed

25

Starts

2022-09-12

Expected to finish

2023-11-17

Last updated by the study team

2025-04-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Suitable candidate for intra-cardiac mapping and ablation of arrhythmias.
• Above eighteen (18) years of age or of legal age to give informed consent specific to state and national law.
• Subjects with a history of documented symptomatic atrial fibrillation.

You may not qualify if…

• Subjects who are not candidates for cardiac ablation procedures.
• Pregnant or nursing.
• Presence of anatomic or comorbid conditions, or other medical, social or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or comply with follow-up requirements.

Where it is running

• Piedmont Healthcare — Athens, Georgia, United States
• Piedmont Atlanta Hospital — Atlanta, Georgia, United States
• Mount Sinai Hospital — New York, New York, United States
• Erasmus MC — Rotterdam, South Holland, Netherlands
• Medicover Hospital — Warsaw, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.